Co-Diagnostics announces $30M share repurchase program

Co-Diagnostics, Inc.

Board authorized up to $30 million of common stock repurchases.
Program is discretionary; company not obligated to buy any specific number of shares.
Management cites strong balance sheet and cash flow generation as supporting the buyback.
Repurchases may be made via open market, block trades, or Rule 10b5-1 plans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.